Revenue: US$29.9m (up 363% from 3Q 2023). Net income: US$54.9m (up from US$2.76m loss in 3Q 2023). EPS: US$0.74 (up from US$0 ...
Key Insights Significantly high institutional ownership implies Ventyx Biosciences' stock price is sensitive to ...